Cambridge-based life science company, EDX Medical Group plc, has entered into a significant partnership with Caris Life Sciences, a US leader in next-generation AI TechBio and precision medicine. This agreement marks a major milestone for EDX Medical as it aligns with a global force in molecular profiling to distribute Caris’ advanced services in the UK and Nordic countries over the next three years.
EDX Medical, located at Cambridge Science Park, is known for its development of digital diagnostic products and services. These offerings are aimed at supporting personalised treatments for major illnesses such as cancer, cardiovascular disease, and infectious diseases. Caris Life Sciences, with its cutting-edge molecular profiling services, uses a proprietary artificial intelligence system to assist physicians in making more precise, patient-specific treatment decisions, particularly in cancer care.
The technology employed by Caris delves deep into the molecular structure of cancerous cells, examining DNA, RNA, and proteins to uncover a detailed blueprint of each patient’s cancer. This allows clinicians to identify the most effective treatment options based on the unique characteristics of the patient’s tumour. Caris boasts one of the world’s most comprehensive cancer analysis platforms, offering advanced tumour profiling that includes Whole Exome and Whole Transcriptome Sequencing across over 23,000 genes. This provides healthcare professionals with valuable insights through the identification of critical biomarkers, thereby enabling more informed, individualised treatment strategies.
Through this new distribution agreement, EDX Medical will have the exclusive right to offer Caris’ solid tumour and liquid biopsy molecular profiling services, alongside AI-driven solutions, in the UK, Sweden, Denmark, Norway, and Finland. These services are expected to become immediately available, with the possibility of expanding to other regions in the future.
Sir Chris Evans, the founder of EDX Medical, emphasised the significance of this collaboration, stating that it represents a critical step forward in their mission to offer world-class diagnostic tools that can dramatically alter the course of treatment for patients. He highlighted the importance of utilising extensive genetic analysis, such as Whole Exome and Transcriptome Sequencing, especially in cases where patients may have limited time or sample availability. Evans expressed confidence in Caris as an ideal partner in this effort to provide superior clinical solutions.
CEO Dr Mike Hudson echoed these sentiments, noting that both EDX Medical and Caris share a common goal: to offer doctors access to the highest quality biological data from patient samples. He expressed pride in EDX being chosen to bring these revolutionary tumour profiling services to key markets in Europe, including the UK.
Caris Life Sciences President, Dr David Spetzler, expressed his enthusiasm for the partnership, reaffirming Caris’ mission to empower clinicians globally with the tools they need to make personalised treatment decisions. He emphasised that this collaboration with EDX Medical is in line with Caris’ broader goals of improving patient outcomes through advanced molecular profiling.
EDX Medical is currently listed on the Apex Segment of the AQSE Growth Market and operates its own facilities in both Cambridge and Oxford. The company provides healthcare professionals, hospitals, and insurers with access to a portfolio of clinical diagnostics that are designed to meet modern medical challenges. Caris Life Sciences, headquartered in Texas, has an international presence with offices in cities including Phoenix, New York, Cambridge (MA), Tokyo, and Basel.
This partnership between EDX Medical and Caris Life Sciences represents a significant advancement in the distribution of sophisticated molecular profiling services. This collaboration aims to provide clinicians with the tools to make more informed, personalised treatment decisions, thereby improving patient care across the UK and the Nordic region.
EDX Medical Group Plc (AQSE:EDX) is a global specialist in digital clinical diagnostics; developing and supporting high-performance products and services to provide cost-effective prediction of disease risk, inform clinical decision-making, enable personalised healthcare and accelerate the development of new medicines for cancer, neurology, heart disease and infectious diseases.
